MX2024011528A - Polipeptidos de fusion sirp-alfa con dominios fc modificados - Google Patents
Polipeptidos de fusion sirp-alfa con dominios fc modificadosInfo
- Publication number
- MX2024011528A MX2024011528A MX2024011528A MX2024011528A MX2024011528A MX 2024011528 A MX2024011528 A MX 2024011528A MX 2024011528 A MX2024011528 A MX 2024011528A MX 2024011528 A MX2024011528 A MX 2024011528A MX 2024011528 A MX2024011528 A MX 2024011528A
- Authority
- MX
- Mexico
- Prior art keywords
- modified
- domains
- fusion polypeptides
- sirp
- alpha fusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323417P | 2022-03-24 | 2022-03-24 | |
| PCT/US2023/064886 WO2023183892A1 (en) | 2022-03-24 | 2023-03-23 | Sirp-alpha fusion polypeptides with modified fc domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011528A true MX2024011528A (es) | 2024-12-06 |
Family
ID=86054071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011528A MX2024011528A (es) | 2022-03-24 | 2024-09-20 | Polipeptidos de fusion sirp-alfa con dominios fc modificados |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230365648A1 (https=) |
| EP (1) | EP4499837A1 (https=) |
| JP (1) | JP2025510774A (https=) |
| KR (1) | KR20240162572A (https=) |
| CN (1) | CN119546769A (https=) |
| AU (1) | AU2023240361A1 (https=) |
| CA (1) | CA3246192A1 (https=) |
| CL (1) | CL2024002849A1 (https=) |
| CO (1) | CO2024013909A2 (https=) |
| IL (1) | IL315706A (https=) |
| JO (1) | JOP20240212A1 (https=) |
| MX (1) | MX2024011528A (https=) |
| WO (1) | WO2023183892A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| US10011660B2 (en) * | 2012-04-30 | 2018-07-03 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| PL3575326T3 (pl) * | 2012-12-17 | 2022-07-11 | Pf Argentum Ip Holdings Llc | Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| PL3180363T3 (pl) | 2014-08-15 | 2020-02-28 | Merck Patent Gmbh | Białka fuzyjne immunoglobulin sirp-alfa |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| CN116239698A (zh) * | 2019-03-06 | 2023-06-09 | 江苏恒瑞医药股份有限公司 | 双功能融合蛋白及其医药用途 |
| EP3976658A4 (en) * | 2019-05-24 | 2023-06-07 | Forty Seven, Inc. | Regimes for co-administration of immunotherapeutic agents against c-kit and cd47 |
| WO2020263830A1 (en) * | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
-
2023
- 2023-03-23 IL IL315706A patent/IL315706A/en unknown
- 2023-03-23 EP EP23718588.9A patent/EP4499837A1/en active Pending
- 2023-03-23 CN CN202380038570.7A patent/CN119546769A/zh active Pending
- 2023-03-23 WO PCT/US2023/064886 patent/WO2023183892A1/en not_active Ceased
- 2023-03-23 AU AU2023240361A patent/AU2023240361A1/en active Pending
- 2023-03-23 KR KR1020247035316A patent/KR20240162572A/ko active Pending
- 2023-03-23 CA CA3246192A patent/CA3246192A1/en active Pending
- 2023-03-23 US US18/189,152 patent/US20230365648A1/en active Pending
- 2023-03-23 JP JP2024556407A patent/JP2025510774A/ja active Pending
-
2024
- 2024-09-20 MX MX2024011528A patent/MX2024011528A/es unknown
- 2024-09-24 CL CL2024002849A patent/CL2024002849A1/es unknown
- 2024-09-29 JO JOJO/P/2024/0212A patent/JOP20240212A1/ar unknown
- 2024-10-16 CO CONC2024/0013909A patent/CO2024013909A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024013909A2 (es) | 2024-10-31 |
| AU2023240361A1 (en) | 2024-10-03 |
| JOP20240212A1 (ar) | 2024-09-29 |
| CL2024002849A1 (es) | 2025-05-23 |
| KR20240162572A (ko) | 2024-11-15 |
| CA3246192A1 (en) | 2023-09-28 |
| WO2023183892A1 (en) | 2023-09-28 |
| IL315706A (en) | 2024-11-01 |
| EP4499837A1 (en) | 2025-02-05 |
| JP2025510774A (ja) | 2025-04-15 |
| US20230365648A1 (en) | 2023-11-16 |
| CN119546769A (zh) | 2025-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000428A1 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana. | |
| MX2023000859A (es) | Composiciones y metodos relacionados con agentes terapeuticos activables. | |
| AR115159A1 (es) | Vesículas extracelulares modificadas y usos de las mismas | |
| AR060827A1 (es) | Metodo para bloquear la infeccion por flavivirus, moleculas y usos | |
| AR063086A1 (es) | Anticuerpos humanos que se unen a cxcr4 y usos de los mismos | |
| CO6491118A2 (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana | |
| GT201000148A (es) | Anticuerpos antimesotelina y usos de los mismos | |
| CL2024000305A1 (es) | Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería | |
| MX2010000944A (es) | Vectores baculovirales que comprenden secuencias de codificacion repetida con deformaciones diferenciales en codones. | |
| GT200900268A (es) | Polipeptidos de factor vii modificados y usos de los mismos . | |
| CL2011003091A1 (es) | Composicion que comprende conjugado covalente entre hemoglobina funcional y nativa y al menos una molecula de polietilenglicol; metodo para preparar composicion; uso de dicha composicion para producir medicina de transfusion. | |
| SV2008002980A (es) | Composiciones y metodos de uso para anticuerpos de dickkopf-1 y/0 -4 | |
| MX2011009242A (es) | Metodo y material para el acomplejamiento activado en el sitio de moleculas biologicas. | |
| CO2023000038A2 (es) | Fusiones heterodiméricas de relaxina y usos de las mismas | |
| PE20152005A1 (es) | Dominios gla como agentes terapeuticos | |
| AR120858A1 (es) | VARIANTES DE a-GLUCOSIDASA ÁCIDA MANIPULADAS POR INGENIERÍA | |
| PE20190966A1 (es) | Factor viii direccionado a los globulos rojos y metodo para su uso | |
| AR122659A1 (es) | Anticuerpos biespecíficos para linfocitos t activados por proteasa | |
| PE20170769A1 (es) | Procedimiento novedoso para la purificacion de rhu-gcsf | |
| BR112023025331A2 (pt) | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso | |
| UY39617A (es) | Proteínas de unión a psma y usos de estas | |
| CL2021002838A1 (es) | Anticuerpo anti-bcma conjugado, composiciones que comprenden el mismo, y métodos de fabricación y uso del mismo. | |
| CO2020013050A2 (es) | Enzimas quinureninasa humanas y sus usos | |
| BR112023018832A2 (pt) | Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas | |
| MX2024011528A (es) | Polipeptidos de fusion sirp-alfa con dominios fc modificados |